Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-02-18

AUTHORS

Roberta Maria Antonello, Stefano Di Bella, Alberto Enrico Maraolo, Roberto Luzzati

ABSTRACT

Fosfomycin (FOS) administered intravenously has been recently rediscovered for the treatment of systemic infections due to multidrug-resistant bacteria. Its pharmacokinetic properties suggest a time-dependent dosing schedule with more clinical benefits from prolonged (PI) or continuous infusion (CI) than from intermittent infusion. We revised literature concerning PI and CI FOS to identify the best dosing regimen based on current evidence. We performed a MEDLINE/PubMed search. Ninety-one studies and their pertinent references were screened. Seventeen studies were included in the present review. The activity of FOS against Gram-negative and Gram-positive bacteria was evaluated in fourteen and five studies, respectively. Six studies evaluated FOS activity in combination with another antibiotic. Daily dosing of 12, 16, 18 or 24 g, administered with different schedules, were investigated. These regimens resulted active against the tested isolates in most cases. Emergence of resistant isolates has been shown to be preventable through the coadministration of another active antibiotic. FOS is a promising option to treat systemic infections caused by multidrug-resistant bacteria. Coadministration with another active molecule is required to prevent the emergence of resistant bacterial strains. The results of our review suggest that a therapeutic regimen including a loading dose of FOS 8 g followed by a daily dose of 16 g or 24 g CI could be the best therapeutic approach for patients with normal renal function. The dosing regimens in patients with renal insufficiency and CI or PI superiority compared with intermittent infusion in clinical settings should be further investigated. More... »

PAGES

1117-1126

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10096-021-04181-x

DOI

http://dx.doi.org/10.1007/s10096-021-04181-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1135455542

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33604721


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bacteria", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bacterial Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Multiple, Bacterial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fosfomycin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127, Trieste, Italy", 
          "id": "http://www.grid.ac/institutes/grid.5133.4", 
          "name": [
            "Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127, Trieste, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Antonello", 
        "givenName": "Roberta Maria", 
        "id": "sg:person.015001711013.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015001711013.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127, Trieste, Italy", 
          "id": "http://www.grid.ac/institutes/grid.5133.4", 
          "name": [
            "Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127, Trieste, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Di Bella", 
        "givenName": "Stefano", 
        "id": "sg:person.01156176207.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156176207.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, 80131, Naples, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "First Division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, 80131, Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maraolo", 
        "givenName": "Alberto Enrico", 
        "id": "sg:person.01211616664.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211616664.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127, Trieste, Italy", 
          "id": "http://www.grid.ac/institutes/grid.5133.4", 
          "name": [
            "Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127, Trieste, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Luzzati", 
        "givenName": "Roberto", 
        "id": "sg:person.0740455776.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740455776.60"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/s41598-019-53714-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122747274", 
          "https://doi.org/10.1038/s41598-019-53714-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-013-0168-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003597975", 
          "https://doi.org/10.1007/s40265-013-0168-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01640831", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000241100", 
          "https://doi.org/10.1007/bf01640831"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02447919", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050649293", 
          "https://doi.org/10.1007/bf02447919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-199753040-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013045058", 
          "https://doi.org/10.2165/00003495-199753040-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01961855", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046086478", 
          "https://doi.org/10.1007/bf01961855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40121-020-00342-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1131099370", 
          "https://doi.org/10.1007/s40121-020-00342-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-02-18", 
    "datePublishedReg": "2021-02-18", 
    "description": "Fosfomycin (FOS) administered intravenously has been recently rediscovered for the treatment of systemic infections due to multidrug-resistant bacteria. Its pharmacokinetic properties suggest a time-dependent dosing schedule with more clinical benefits from prolonged (PI) or continuous infusion (CI) than from intermittent infusion. We revised literature concerning PI and CI FOS to identify the best dosing regimen based on current evidence. We performed a MEDLINE/PubMed search. Ninety-one studies and their pertinent references were screened. Seventeen studies were included in the present review. The activity of FOS against Gram-negative and Gram-positive bacteria was evaluated in fourteen and five studies, respectively. Six studies evaluated FOS activity in combination with another antibiotic. Daily dosing of 12, 16, 18 or 24 g, administered with different schedules, were investigated. These regimens resulted active against the tested isolates in most cases. Emergence of resistant isolates has been shown to be preventable through the coadministration of another active antibiotic. FOS is a promising option to treat systemic infections caused by multidrug-resistant bacteria. Coadministration with another active molecule is required to prevent the emergence of resistant bacterial strains. The results of our review suggest that a therapeutic regimen including a loading dose of FOS 8 g followed by a daily dose of 16 g or 24 g CI could be the best therapeutic approach for patients with normal renal function. The dosing regimens in patients with renal insufficiency and CI or PI superiority compared with intermittent infusion in clinical settings should be further investigated.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10096-021-04181-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1093599", 
        "issn": [
          "0934-9723", 
          "1435-4373"
        ], 
        "name": "European Journal of Clinical Microbiology & Infectious Diseases", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "40"
      }
    ], 
    "keywords": [
      "continuous infusion", 
      "multidrug-resistant bacteria", 
      "intermittent infusion", 
      "systemic infection", 
      "MEDLINE/PubMed search", 
      "best dosing regimen", 
      "normal renal function", 
      "more clinical benefits", 
      "best therapeutic approach", 
      "systemic bacterial infection", 
      "activity of fosfomycin", 
      "renal insufficiency", 
      "daily dosing", 
      "renal function", 
      "dosing schedules", 
      "dosing regimen", 
      "loading dose", 
      "daily dose", 
      "therapeutic regimen", 
      "clinical benefit", 
      "prolonged infusion", 
      "clinical studies", 
      "therapeutic approaches", 
      "current evidence", 
      "PubMed search", 
      "systematic review", 
      "bacterial infections", 
      "infusion", 
      "clinical setting", 
      "pharmacokinetic properties", 
      "resistant isolates", 
      "active antibiotics", 
      "resistant bacterial strains", 
      "fosfomycin", 
      "infection", 
      "different schedules", 
      "regimen", 
      "coadministration", 
      "patients", 
      "Fos activity", 
      "dose", 
      "present review", 
      "antibiotics", 
      "review", 
      "pertinent references", 
      "Gram-positive bacteria", 
      "most cases", 
      "regimens", 
      "isolates", 
      "dosing", 
      "insufficiency", 
      "study", 
      "promising option", 
      "treatment", 
      "schedule", 
      "vivo", 
      "activity", 
      "bacteria", 
      "bacterial strains", 
      "options", 
      "setting", 
      "active molecules", 
      "evidence", 
      "cases", 
      "benefits", 
      "Gram", 
      "strains", 
      "search", 
      "combination", 
      "function", 
      "emergence", 
      "literature", 
      "PI", 
      "results", 
      "molecules", 
      "reference", 
      "superiority", 
      "approach", 
      "properties", 
      "proposal"
    ], 
    "name": "Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies", 
    "pagination": "1117-1126", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1135455542"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10096-021-04181-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33604721"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10096-021-04181-x", 
      "https://app.dimensions.ai/details/publication/pub.1135455542"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_886.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10096-021-04181-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10096-021-04181-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10096-021-04181-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10096-021-04181-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10096-021-04181-x'


 

This table displays all metadata directly associated to this object as RDF triples.

234 TRIPLES      22 PREDICATES      123 URIs      108 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10096-021-04181-x schema:about N01fd8d4d36f9486c85885e8960f29110
2 N03f2cffc23894c0fad1e050220b5a218
3 N597229ca451a4d8e96ec1f725f5513d0
4 N64e0bc17b6c44e95860d67354a5c251c
5 N82826b6729da4b528df2ba4588896fa1
6 Na740d4c504744982a0fdb8b0dfc55b40
7 Nb207cb8c5b2645a99f5730255ac1dee4
8 Nbfacb3d4bac245229f4a9b305bf01c81
9 Nc598a8890418486c8433ecbb8294cbb6
10 Nd132857d901942c087626352ae3461b6
11 anzsrc-for:11
12 anzsrc-for:1103
13 schema:author N086c7b40e36f47f8a596e7e01b14f342
14 schema:citation sg:pub.10.1007/bf01640831
15 sg:pub.10.1007/bf01961855
16 sg:pub.10.1007/bf02447919
17 sg:pub.10.1007/s40121-020-00342-1
18 sg:pub.10.1007/s40265-013-0168-2
19 sg:pub.10.1038/s41598-019-53714-0
20 sg:pub.10.2165/00003495-199753040-00007
21 schema:datePublished 2021-02-18
22 schema:datePublishedReg 2021-02-18
23 schema:description Fosfomycin (FOS) administered intravenously has been recently rediscovered for the treatment of systemic infections due to multidrug-resistant bacteria. Its pharmacokinetic properties suggest a time-dependent dosing schedule with more clinical benefits from prolonged (PI) or continuous infusion (CI) than from intermittent infusion. We revised literature concerning PI and CI FOS to identify the best dosing regimen based on current evidence. We performed a MEDLINE/PubMed search. Ninety-one studies and their pertinent references were screened. Seventeen studies were included in the present review. The activity of FOS against Gram-negative and Gram-positive bacteria was evaluated in fourteen and five studies, respectively. Six studies evaluated FOS activity in combination with another antibiotic. Daily dosing of 12, 16, 18 or 24 g, administered with different schedules, were investigated. These regimens resulted active against the tested isolates in most cases. Emergence of resistant isolates has been shown to be preventable through the coadministration of another active antibiotic. FOS is a promising option to treat systemic infections caused by multidrug-resistant bacteria. Coadministration with another active molecule is required to prevent the emergence of resistant bacterial strains. The results of our review suggest that a therapeutic regimen including a loading dose of FOS 8 g followed by a daily dose of 16 g or 24 g CI could be the best therapeutic approach for patients with normal renal function. The dosing regimens in patients with renal insufficiency and CI or PI superiority compared with intermittent infusion in clinical settings should be further investigated.
24 schema:genre article
25 schema:inLanguage en
26 schema:isAccessibleForFree true
27 schema:isPartOf N2dfa09a760274c778e60fca8e186afd1
28 Nad3aa874e4f84e70a95c7a6d2021c464
29 sg:journal.1093599
30 schema:keywords Fos activity
31 Gram
32 Gram-positive bacteria
33 MEDLINE/PubMed search
34 PI
35 PubMed search
36 active antibiotics
37 active molecules
38 activity
39 activity of fosfomycin
40 antibiotics
41 approach
42 bacteria
43 bacterial infections
44 bacterial strains
45 benefits
46 best dosing regimen
47 best therapeutic approach
48 cases
49 clinical benefit
50 clinical setting
51 clinical studies
52 coadministration
53 combination
54 continuous infusion
55 current evidence
56 daily dose
57 daily dosing
58 different schedules
59 dose
60 dosing
61 dosing regimen
62 dosing schedules
63 emergence
64 evidence
65 fosfomycin
66 function
67 infection
68 infusion
69 insufficiency
70 intermittent infusion
71 isolates
72 literature
73 loading dose
74 molecules
75 more clinical benefits
76 most cases
77 multidrug-resistant bacteria
78 normal renal function
79 options
80 patients
81 pertinent references
82 pharmacokinetic properties
83 present review
84 prolonged infusion
85 promising option
86 properties
87 proposal
88 reference
89 regimen
90 regimens
91 renal function
92 renal insufficiency
93 resistant bacterial strains
94 resistant isolates
95 results
96 review
97 schedule
98 search
99 setting
100 strains
101 study
102 superiority
103 systematic review
104 systemic bacterial infection
105 systemic infection
106 therapeutic approaches
107 therapeutic regimen
108 treatment
109 vivo
110 schema:name Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies
111 schema:pagination 1117-1126
112 schema:productId N2114dc71030141fea701dbb78e3499a3
113 N2fb0191081294814bdaccbd3758c9067
114 N7e235588ce744242b80b2bc0edca1886
115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1135455542
116 https://doi.org/10.1007/s10096-021-04181-x
117 schema:sdDatePublished 2022-05-20T07:38
118 schema:sdLicense https://scigraph.springernature.com/explorer/license/
119 schema:sdPublisher Ncc7a068e4edd4b5a8ee63415200e4481
120 schema:url https://doi.org/10.1007/s10096-021-04181-x
121 sgo:license sg:explorer/license/
122 sgo:sdDataset articles
123 rdf:type schema:ScholarlyArticle
124 N01fd8d4d36f9486c85885e8960f29110 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Anti-Bacterial Agents
126 rdf:type schema:DefinedTerm
127 N03f2cffc23894c0fad1e050220b5a218 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Dose-Response Relationship, Drug
129 rdf:type schema:DefinedTerm
130 N086c7b40e36f47f8a596e7e01b14f342 rdf:first sg:person.015001711013.54
131 rdf:rest N4761988972544c369da8cdc933659b31
132 N2114dc71030141fea701dbb78e3499a3 schema:name pubmed_id
133 schema:value 33604721
134 rdf:type schema:PropertyValue
135 N2dfa09a760274c778e60fca8e186afd1 schema:issueNumber 6
136 rdf:type schema:PublicationIssue
137 N2fb0191081294814bdaccbd3758c9067 schema:name dimensions_id
138 schema:value pub.1135455542
139 rdf:type schema:PropertyValue
140 N4761988972544c369da8cdc933659b31 rdf:first sg:person.01156176207.36
141 rdf:rest Na0ed73ad843d4aa8a7293e2d95782049
142 N548e7959b0b943afa3a2b7f249e0c31f rdf:first sg:person.0740455776.60
143 rdf:rest rdf:nil
144 N597229ca451a4d8e96ec1f725f5513d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Humans
146 rdf:type schema:DefinedTerm
147 N64e0bc17b6c44e95860d67354a5c251c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Time Factors
149 rdf:type schema:DefinedTerm
150 N7e235588ce744242b80b2bc0edca1886 schema:name doi
151 schema:value 10.1007/s10096-021-04181-x
152 rdf:type schema:PropertyValue
153 N82826b6729da4b528df2ba4588896fa1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Bacterial Infections
155 rdf:type schema:DefinedTerm
156 Na0ed73ad843d4aa8a7293e2d95782049 rdf:first sg:person.01211616664.17
157 rdf:rest N548e7959b0b943afa3a2b7f249e0c31f
158 Na740d4c504744982a0fdb8b0dfc55b40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Infusions, Intravenous
160 rdf:type schema:DefinedTerm
161 Nad3aa874e4f84e70a95c7a6d2021c464 schema:volumeNumber 40
162 rdf:type schema:PublicationVolume
163 Nb207cb8c5b2645a99f5730255ac1dee4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Drug Administration Schedule
165 rdf:type schema:DefinedTerm
166 Nbfacb3d4bac245229f4a9b305bf01c81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Bacteria
168 rdf:type schema:DefinedTerm
169 Nc598a8890418486c8433ecbb8294cbb6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Fosfomycin
171 rdf:type schema:DefinedTerm
172 Ncc7a068e4edd4b5a8ee63415200e4481 schema:name Springer Nature - SN SciGraph project
173 rdf:type schema:Organization
174 Nd132857d901942c087626352ae3461b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Drug Resistance, Multiple, Bacterial
176 rdf:type schema:DefinedTerm
177 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
178 schema:name Medical and Health Sciences
179 rdf:type schema:DefinedTerm
180 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
181 schema:name Clinical Sciences
182 rdf:type schema:DefinedTerm
183 sg:journal.1093599 schema:issn 0934-9723
184 1435-4373
185 schema:name European Journal of Clinical Microbiology & Infectious Diseases
186 schema:publisher Springer Nature
187 rdf:type schema:Periodical
188 sg:person.01156176207.36 schema:affiliation grid-institutes:grid.5133.4
189 schema:familyName Di Bella
190 schema:givenName Stefano
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156176207.36
192 rdf:type schema:Person
193 sg:person.01211616664.17 schema:affiliation grid-institutes:None
194 schema:familyName Maraolo
195 schema:givenName Alberto Enrico
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211616664.17
197 rdf:type schema:Person
198 sg:person.015001711013.54 schema:affiliation grid-institutes:grid.5133.4
199 schema:familyName Antonello
200 schema:givenName Roberta Maria
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015001711013.54
202 rdf:type schema:Person
203 sg:person.0740455776.60 schema:affiliation grid-institutes:grid.5133.4
204 schema:familyName Luzzati
205 schema:givenName Roberto
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740455776.60
207 rdf:type schema:Person
208 sg:pub.10.1007/bf01640831 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000241100
209 https://doi.org/10.1007/bf01640831
210 rdf:type schema:CreativeWork
211 sg:pub.10.1007/bf01961855 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046086478
212 https://doi.org/10.1007/bf01961855
213 rdf:type schema:CreativeWork
214 sg:pub.10.1007/bf02447919 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050649293
215 https://doi.org/10.1007/bf02447919
216 rdf:type schema:CreativeWork
217 sg:pub.10.1007/s40121-020-00342-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1131099370
218 https://doi.org/10.1007/s40121-020-00342-1
219 rdf:type schema:CreativeWork
220 sg:pub.10.1007/s40265-013-0168-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003597975
221 https://doi.org/10.1007/s40265-013-0168-2
222 rdf:type schema:CreativeWork
223 sg:pub.10.1038/s41598-019-53714-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122747274
224 https://doi.org/10.1038/s41598-019-53714-0
225 rdf:type schema:CreativeWork
226 sg:pub.10.2165/00003495-199753040-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013045058
227 https://doi.org/10.2165/00003495-199753040-00007
228 rdf:type schema:CreativeWork
229 grid-institutes:None schema:alternateName First Division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, 80131, Naples, Italy
230 schema:name First Division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, 80131, Naples, Italy
231 rdf:type schema:Organization
232 grid-institutes:grid.5133.4 schema:alternateName Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127, Trieste, Italy
233 schema:name Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127, Trieste, Italy
234 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...